Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Brea
Go back to Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Brea| PUMA BIOTECHNOLOGY, Inc. (NASDAQ: PBYI) | Delayed: 7.73 +0.17 (2.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.56 | 52 Week High | $82.81 | |||
| Open | $7.60 | 52 Week Low | $19.74 | |||
| Day High | $7.87 | P/E | N/A | |||
| Day Low | $7.59 | EPS | $-2.16 | |||
| Volume | 88,730 | |||||
